NovaBridge rises as stomach cancer drug combo gets FDA fast-track status

NovaBridge Biosciences

16/06/2026 12:17

** Shares of drug developer NovaBridge NBP.O rise 10.8% to $1.63 premarket 
** Co says FDA granted fast-track status to experimental drug givastomig with nivolumab and chemotherapy for advanced gastric cancer
** Gastric cancer is a cancer of the stomach; the combo targets specific tumor markers and helps the immune system attack cancer cells
** Says early-stage study showed durable tumor shrinkage with manageable side effects
** Says it plans late-stage study start in Q4 2026, with detailed mid-stage data due in H2 2026
** Co's givastomig is a bispecific antibody being developed with ABL Bio to target tumors and activate immune cells - NBP
** Fast-track status aims to speed development and review for drugs addressing serious diseases with unmet medical needs
** As of last close, stock down ~63% YTD
  
 

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))